Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Cognitive
Hepatocyte growth factor mimetic — claimed to be 7 orders of magnitude more potent than BDNF.
Peptide B
Cognitive
Neuroprotective ACTH analog with nootropic and neurotrophic properties.
Typical vial
30 mg
Typical dose
8,000-45,000 (oral) mcg
Half-life
~3-4 hours (oral)
FDA status
Not FDA approved. The related HGF-positive modulator fosgoni…
Typical vial
5 mg
Typical dose
200-600 mcg
Half-life
~2-3 minutes (very rapid degradation; biological effects last hours due to downstream gene expression changes)
FDA status
Not FDA approved for human use. Approved in Russia for strok…
Dihexa effects
Semax effects
Dihexa side effects
Semax side effects
Dihexa dosing ranges
Cognitive research (oral / sublingual)
8-45 mg · Once daily · 30 days per cycle
Semax dosing ranges
Cognitive enhancement
200-600 mcg · Once or twice daily (intranasal) · 10-20 days per course
Neuroprotection / stroke recovery
600-1200 mcg · Two to three times daily (intranasal) · 10-14 days
Dihexa: Hepatocyte growth factor mimetic — claimed to be 7 orders of magnitude more potent than BDNF. Typical dose 8,000-45,000 (oral) mcg. Semax: Neuroprotective ACTH analog with nootropic and neurotrophic properties. Typical dose 200-600 mcg. Both fall under the Cognitive category.
Stacking Dihexa with Semax is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Dihexa is typically dosed: Once daily for Cognitive research (oral / sublingual). Semax is typically dosed: Once or twice daily (intranasal) for Cognitive enhancement; Two to three times daily (intranasal) for Neuroprotection / stroke recovery.
Dihexa: Not FDA approved. The related HGF-positive modulator fosgonimeton (ATH-1017) is in clinical trials for Alzheimer's. Semax: Not FDA approved for human use. Approved in Russia for stroke recovery, cognitive impairment, and optic nerve disease.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free